On Tuesday, 28May2019 (8:30 am PDT/11:30 am EDT), we will be holding an teleconference to collect input and comments on the new FDA draft guidance document "Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry" (URL below). We will then ask AAPS to submit the finalized comments to FDA on the Community's behalf. Call-in information will be provided upon request.